Myasthenia Gravis (MG)



When nerve impulse transmission is interrupted at the neuromuscular junction where nerve cells and muscles connect, due to acetylcholine receptors being blocked or destroyed by antibodies. Acetylcholine receptors activate muscle contractions; thus, their destruction prevents those contractions from occurring.

Common Symptoms

Weakness of the extrinsic ocular muscles and include drooping of the eyelids, blurred or double vision, difficulty swallowing, shortness of breath, impaired speech, and weakness in the arms, hands, fingers, legs, and neck. MG can also lead to respiratory failure.

Coexisting Diseases and Conditions

Thyroiditis, rheumatoid arthritis, systemic lupus erythematosus, neuromyelitis optica spectrum disorder, and myocarditis.

For Healthcare Providers (CME/CE credit)

Evidence-Based Management of Generalized Myasthenia Gravis: Current Practices and Emerging Treatment Paradigms

Tune in as renowned experts discuss the underlying pathophysiology and diverse clinical manifestations of gMG, best diagnostic practices, the latest evidence on current and emerging treatments, and collaborative strategies to address the long-term, multisystemic impact of gMG.

This activity is delivered by PRIME Education.


  1. Article Sources
    1. Jayam Trouth, A., Dabi, A., Solieman, N., Kurukumbi, M., & Kalyanam, J. (2012). Myasthenia Gravis: A Review. Autoimmune Diseases, 2012, e874680.

    2. Myasthenia Gravis Fact Sheet | National Institute of Neurological Disorders and Stroke. (n.d.). Retrieved July 9, 2021, from

    3. Sieb, J. P. (2014). Myasthenia gravis: An update for the clinician. Clinical & Experimental Immunology, 175(3), 408–418.